Welcome to our dedicated page for SI-BONE SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SI-BONE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SI-BONE's regulatory disclosures and financial reporting.
SI-BONE, Inc. reporting person Anthony J. Recupero reported multiple open-market sales of common stock on February 17, 2026 totaling 21,049 shares at weighted-average prices around the mid‑$15 range. The filing states these shares were sold under a “sell to cover” arrangement to satisfy tax withholding obligations from vesting restricted stock units, and therefore were not discretionary trades. After these sales, Recupero reported ownership of 243,418 shares of common stock, which the footnotes state includes 83,423 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. reported that executive Michael A. Pisetsky, SVP of Operations & Administration and Chief Legal Officer, received several stock awards and sold shares primarily to cover taxes. On February 16, 2026, he acquired 58,720 shares of common stock and two additional grants of 9,787 shares each as restricted stock unit awards, at a stated price of $0.00 per share, reflecting equity compensation that will vest over multi-year periods based on service and, for one grant, relative total shareholder return performance.
On February 17, 2026, he executed open-market sales totaling 20,756 shares of common stock at weighted average prices around $15.31–$15.41 per share. Footnotes state these sales were required to satisfy tax withholding obligations from RSU vesting through “sell to cover” transactions and were not discretionary trades. After these transactions, he continued to hold a substantial share position, including 157,176 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. director and Chief Executive Officer Laura Francis reported a mix of stock awards and sales. On February 16, 2026, she acquired a total of 229,481 shares of common stock through grants and restricted stock unit awards at a stated price of $0.00 per share, which will vest over three to four years based on time and total shareholder return performance conditions. On February 17, 2026, she sold 93,475 shares of common stock in a series of open-market transactions at weighted average prices around $15.30 per share to cover tax withholding obligations from vesting restricted stock units, as disclosed in a footnote. Following these sales, she directly owned 544,369 shares, including 414,439 shares issuable upon settlement of restricted stock units, and an additional 351,319 shares were held indirectly by The David & Laura Joint Rev Tr.
SI-BONE, Inc.’s Chief Financial Officer Anshul Maheshwari reported a mix of equity awards and related share sales. On February 16, 2026, he acquired a total of 107,992 shares of common stock through grants of restricted stock units, which vest over multi‑year periods based on time and total shareholder return performance.
On February 17, 2026, he sold 21,528 shares of common stock in multiple open‑market transactions at prices between $15.18 and $15.62. Footnotes state these sales were solely to cover tax withholding obligations from RSU vesting under a sell‑to‑cover arrangement and were not discretionary trades.
OrbiMed Capital LLC and OrbiMed Advisors LLC report that they no longer own any shares of SI-BONE, Inc. common stock. As of the event date of 12/31/2025, each reporting person discloses beneficial ownership of 0 shares, representing 0.0% of SI-BONE’s common stock.
They report no sole or shared voting or dispositive power over any SI-BONE shares and confirm they now own 5 percent or less of the class. The firms state the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE.
American Century entities and the Stowers Institute report significant ownership stakes in Si-Bone, Inc. common stock in an amended Schedule 13G. American Century Investment Management, American Century Companies, and the Stowers Institute each report beneficial ownership of 2,300,508 shares, representing 5.3% of the class.
American Century Mutual Funds separately reports beneficial ownership of 1,779,575 shares, or 4.1% of the common stock. The filers certify that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Si-Bone.
SI-BONE, Inc. (SIBN) received an updated Schedule 13G/A from Brown Advisory and related entities reporting their passive ownership in the company’s common stock as of 12/31/2025. Brown Advisory Inc and its listed subsidiaries report beneficial ownership of 2,513,268 shares, representing 5.79 % of the outstanding common stock.
The shares are held across multiple affiliated entities, including Brown Advisory LLC, Brown Investment Advisory & Trust, Signature Financial Management, Inc., and Brown Advisory Ltd, largely through investment companies and managed accounts. The group certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE.
Champlain Investment Partners, LLC reported beneficial ownership of 2,108,944 shares of SI-BONE, Inc. common stock, representing 4.9% of the class as of 09/30/2025. Champlain has sole voting power over 1,337,489 shares and sole dispositive power over 2,108,944 shares, with no shared voting or dispositive power.
The firm files as an institutional investment adviser and certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose or effect of changing or influencing control of SI-BONE, Inc.
SI-BONE, Inc. director Jeffrey W. Dunn reported a small sale of company stock tied to tax obligations. On February 2, 2026, he sold 337 shares of common stock at a weighted average price of $16.4157 per share.
The footnotes explain this was a mandatory "sell to cover" transaction to satisfy tax withholding from vesting restricted stock units, and not a discretionary trade. After the sale, Dunn beneficially owned 9,970 shares directly, including 9,491 shares issuable upon settlement of restricted stock units, and 80,115 shares indirectly held by The Jeffrey W. Dunn Living Trust Dated May 17, 2012.
SI-BONE director Jeffrey W. Dunn, through The Jeffrey W. Dunn Living Trust Dated May 17, 2012, reported selling 20,000 shares of SI-BONE common stock on January 8, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated May 7, 2025 at a weighted-average price of $21.2753 per share, with individual trade prices ranging from $20.84 to $21.84.
Following the sale, the trust held 80,115 shares indirectly, while Dunn also had 10,307 shares directly, including shares issuable upon settlement of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of SI-BONE common stock.